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IL-2 is a  T  cell-derived soluble factor with a  broad spectrum of growth and 
differentiation-promoting activities (1). It provides a signal for cell proliferation 
by binding to high-affinity receptors on responsive cell populations.  IL-2 recep- 
tors are expressed by activated T  cells, and their functional importance has been 
shown in vivo (2). Administration of IL-2 in vivo specifically enhances allogeneic 
responses and allows induction of cytotoxic and helper T  cells in nude mice and 
in  cyclophosphamide-treated  animals  (3-5).  The  recent  finding  (6)  of  IL-2 
receptors on  B  cells suggest  that  IL-2  might  also  exert a  function as  a  B  cell 
growth and differentiation factor.  We wished  to explore the functional role of 
IL-2 in the initiation and differentiation of a humoral immune response in vivo. 
IL-2 given in vivo could potentially affect humoral responsiveness by two differ- 
ent mechanisms: amplification of B cell responses by expansion of the helper cell 
pool, and/or by direct stimulation of B cells. We report here that administration 
of rIL-2 in vivo caused polyclonal IgM production. Treatment with rIL-2 clearly 
augmented  the  IgM  production  in  primary as  well  as  secondary  immune  re- 
sponses, but it did not affect IgG secretion, nor did it induce a class switch from 
IgM to IgG in genetically low-responding mice. 
Materials and Methods 
Animals.  BALB/c, A/J,  A.BY  mice and  Swiss nude  mice were bred in  the  animal 
facilities at Stanford University, or were purchased from The Jackson  Laboratory, Bar 
Harbor, ME. 
IL-2.  rIL-2  was  kindly supplied  by the  Cetus  Corp.,  Emeryville, CA  (lots  LP222, 
LP236, and LP265B). Endotoxin concentration was <0.05 ng per 106 U IL-2, as measured 
in a Limulus assay. A buffer control from E. coli that did not contain the IL-2 insert but 
was equivalent in all other respects was used in the control mice. 
Determination  of Antibody  Titers.  Concentrations of antibodies in the sera were meas- 
ured by solid-phase ELISA (7). 
Estimation  of Precursor Frequencies in Limiting-dilution  Assays.  Precursor frequencies of 
antigen-specific proliferative T cells were determined in a limiting-dilution system. Briefly, 
DBA/2 mice were immunized with  100 #g soluble sperm whale myoglobin (SpWMb) at 
the base  of the  tail and injected with  nine doses of 5,000  U  rIL-2 i.p.  for 3  d  after 
immunization.  Controls received excipient buffer instead  of rIL-2.  Regional  draining 
lymph nodes were harvested on day 8 after immunization. Limited numbers of lymph 
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FICVRE  1.  Effects of treatment with rIL-2 in vivo on humoral responses. BALB/c mice were 
either not immunized or immunized with 100 ug soluble SpWMb (Sigma Chemical Co.,  St. 
Louis, MO) or  100 #g SpWMb dissolved in CFA i.p. AB.Y mice received 100 ug (H,G)-A-L 
(a gift of Dr. H. O. M. McDevitt, Stanford University) in CFA. On day 14 mice were challenged 
with 50 #g aqueous antigen or 10 t~g antigen in IFA. Mice were treated with either three daily 
doses of 5,000  U  rIL-2 (shaded bars) or excipient control buffer (open bars), the three days 
after each immunization. SpWMb-specific IgM (A) and IgG concentrations (B) were measured 
on day 6  after the primary immunization, and on day 5  after the secondary immunization. 
Antibody concentrations to (H,G)-A-L were obtained on day 7 of the secondary response. Bars 
are mean antibody concentrations of 3-5 mice/group, SEM was <20%. 
node  cells (80,000-625  cells/well)  were  expanded  in  the  presence  of  106  syngeneic 
irradiated spleen cells and 10 #M SpWMb in flat-bottom,  96-well microtiter plates (Linbro, 
McLean,  VA).  20 U/ml  of rIL-2  were added at  the beginning of the culture period. 
Microcultures  were fed on day 7. On day 12, the cultures were washed three times and 
restimulated  with  fresh  feeder cells and  SpWMb in  the  absence  of exogenous  IL-2. 
Proliferation was assessed byyH]thymidine incorporation after 72 h. Individual  cultures 
were scored positive when  [ H]thymidine incorporation exceeded background levels of 
control cultures by more than  three standard deviations.  Data were analyzed by Poisson 
analysis. 
ResuLts and Discussion 
Treatment with rIL-2 In Vivo Induced Polyclonal IgM Production.  To study the 
role of rIL-2 in a humoral immune response in vivo, mice were treated with rIL- 
2 for 3 d after immunization with a soluble antigen. Conventional immunization 
with soluble SpWMb induced the production of IgM antibodies in the primary 
response and a  mixture  of IgM and  IgG antibodies  in  the secondary response 
(Fig.  1). When SpWMb was given in CFA, the animals produced IgM and IgG 
anti-SpWMb  antibodies  in  the  primary  response  and  showed  increased  IgG 
concentrations after secondary antigen challenge (Fig.  1). Treatment with three 
daily  doses of 5,000  U  rIL-2  injected  after  immunization  caused a  3-10-fold 
increase  in  the  IgM  titers  to  both  antigens.  Administration  of rIL-2  did  not 
influence 1gG production in any of the experimental groups. Surprisingly, mice 
treated  with  r|L-2  alone  without  exogenous antigen  also  developed  elevated 
titers of antibodies specific to SpWMb (Fig.  1 a). Such antibodies induced by the 
rlL-2  injection  were exclusively IgM.  The  second series of rIL-2  injections on 
days 15,  16, and  17 was again followed by the production of anti-SpWMb IgM 
antibodies. To exclude a possible nonspecific effect and to analyze the spectrum 
of IgM antibodies produced in rIL-2-treated mice, sera from rIL-2-treated mice 
were tested for their anti-KLH  reactivity.  All mice that  received high  doses of 
rIL-2 produced IgM (but not IgG) antibodies against KLH (Fig.  2). To analyze 
the  specificity of the  rIL-2-induced  IgM  antibodies,  we absorbed  pooled  sera WEYAND ET  AL.  BRIEF  DEFINITIVE REPORT  1609 
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FIGURE 2.  Humoral responses to unrelated antigen after treatment with rIL-2 or immuni- 
zation with antigen. Anti KLH (Calbiochem-Behring,  San Diego, CA) IgM antibodies were 
measured in BALB/c mice that were either not immunized,  immunized  with aqueous SpWMb, 
or with SpWMB in CFA. Mice were treated with control buffer (open bars) or with rIL-2 
(shaded bars), and sera were collected, as described in Fig. 1. IgM antibodies against KLH 
were measured. Data represent the means of groups of five mice. 
from five BALB/c mice on SpWMb-coupled plates. After repeated absorptions, 
the antibodies binding to SpWMb  were removed  without altering the titer of 
anti-KLH antibodies (data not shown). This result showed that antibodies with 
different  specificities  were  present  in  sera  of  mice  treated  with  rIL-2,  and 
suggested  the  possibility  that  rIL-2  induced  a  polyclonai  stimulation  of IgM 
antibody production.  Similar effects (i.e.,  three-  to  sixfold-increased antibody 
responses)  were obtained when BALB/c mice were immunized with KLH and 
when A/J mice were given (H,G)-A-L followed by rlL-2 (data not presented). 
Treatment with rlL-2 In Vivo Induced Polyclonal  T Cell Activation.  It is conceiv- 
able that rIL-2 primarily expanded the pool of antigen-specific T  cells, and thus 
secondarily affected B cell function. To analyze the possibility of a direct effect 
of injected  rIL-2  on  T  cells,  a  limiting-dilution  system  was  established  that 
allowed the estimation of precursor frequencies of SpWMb-specific proliferative 
T  cells.  In  naive  DBA/2  mice,  1  in  40,120  lymph node  cells  proliferated  in 
response  to  SpWMB  (Fig.  3).  After a  single  immunization with  SpWMb,  the 
frequency of proliferative T  cell  precursors  in regional  draining lymph nodes 
increased  ~3.5-fold  to  1  in  11,625.  Lymph  nodes  of rIL-2-treated  animals 
contained as many SpWMb-specific proliferative T  cells as did animals immunized 
with SpWMb (1  in  12,410).  Injection of rIL-2  in vivo in addition to SpWMb, 
further  increased  SpWMb-specific  proliferative  T  cells  to a  frequency of 1 in 
4,530. 
Immunization  with  Specific  Antigen  Induced  a  Polyclonal  IgM  Response.  Ac- 
tivation of T  lymphocytes by specific antigen is generally accompanied by the 
release of endogenous IL-2. To test the hypothesis that exogenous rIL-2 might 
mimic a physiological effect of locally released IL-2 we measured antibody titers 
against  the  unrelated  antigen  KLH  in  the  sera  of SpWMb  immunized  mice. 
Similar to results seen in rIL-2 treated mice,  IgM antibodies specific for KLH 
were found after immunization with SpWMb (Fig. 2). 
Potential Mechanisms  of Action  of rlL-2 In  Vivo.  In contrast to recently pub- 
lished data (8), we did not find an effect of rIL-2 on IgG antibody production, 
nor could we overcome Ir gene-controlled low responsiveness. Our observation 
that the injection of rIL-2 enhanced the production of antigen-specific antibodies 
might be explained by a  direct effect of rlL-2 on the antigen-specific helper T 
cells.  In  our  analysis  of the  T  cell  repertoire,  similar  frequencies  of T  cells 
responded  to  SpWMb  in  immunized  and  unimmunized  rIL-2-treated  mice. 1610  WEYAND  ET  AL  BRIEF  DEFINITIVE  REPORT 
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FIGURE 3.  Precursor frequencies of antigen-specific proliferative T cells. BALB/c mice were 
immunized with 100 t~g aqueous SpWMb and were treated with either rIL-2 (I) or excipient 
control buffer (0) for 3 d after antigen injection. Control mice received rIL-2 (A) or excipient 
control  buffer (O)  in  the  absence of any  exogenous antigen.  Draining lymph  nodes were 
harvested on  day  8  after  immunization, and  limiting-dilution analyses were  performed  as 
described in Materials and Methods. 
However, the frequency of SpWMb-reactive T  cells after administration of both 
antigen  and  IL-2  seemed additive  (Fig.  3).  Not  only did  we  see this  additive 
effect at  the  level  of T  cell  precursor  frequencies,  but  IgM  antibodies  were 
additionally enhanced in the presence of IL-2 and antigen compared with either 
antigen or IL-2 alone (Fig.  1). The implications of these findings are interesting 
but currently unexplained. 
In studies reported in this paper, the effect of exogenous rIL-2 was restricted 
to an augmentation  of IgM production  suggesting that  the adjuvant-like effect 
of rIL-2  is isotype selective.  A  random  expansion  of antigen-specific helper  T 
cells might  be  expected  to  affect both  ]gM  and  IgG  responses.  However, as 
reported from our laboratory and elsewhere, helper T cells have two independent 
pathways  of help  (7,  9),  and  it  is  possible  that  rIL-2  activates  only  the  IgM 
pathway. Alternatively,  there might be a direct effect of high  doses of rIL-2 in 
vivo on  lgM-producing  B cells.  B cell  responses are regulated by a  number of 
antigen-nonspecific,  genetically  unrestricted  factors derived from  T  cells (10). 
Recently (6), the expression of functional IL-2 receptors on activated B cells was 
shown using anti-Tac, an mAb against the IL-2 receptor molecule and by binding 
studies  with  purified  radiolabelled  IL-2.  High  doses of rIL-2  showed definite 
activity as a  differentiation  factor in  IgM synthesis in  vitro (11).  Other  studies 
(12) have suggested that IL-2 can function in B cell proliferation induction. The 
concentrations  necessary for the  B cell differentiative activity in  vitro (100  U/ 
ml) or for B cell proliferation  were probably achieved transiently in our model. 
In  our  immunization  protocol,  the  administration  of exogenous  rIL-2  might 
provide a proliferative signal and/or a terminal differentiation signal to selected 
B cells resulting in a high rate of IgM synthesis and secretion. 
To test the hypothesis that rI L-2 may have a direct effect on B cells, we studied 
rIL-2  in  three  different  T  cell-depleted  (deficient)  animal  models:  the  nude 
mouse,  the  thymectomized,  irradiated,  bone  marrow-reconstituted  mouse 
(ATxBm), and the T  helper cell-depleted mouse (by repeated treatment in vivo 
with anti-L3T4 mAb). Swiss nude mice, which received a total dose of 45,000 U 
rIL-2 over 3 d  produced equivalent amounts of IgM anti-SpWMb compared to 
Swiss nu/+ controls (data not shown).  The  nude mouse may be not an optimal 
system to study  T  cell-independent  effects.  Residual  T  cell  precursors  might 
differentiate without thymic influence, especially in the presence of exogenous 
IL-2. Additional evidence that rIL-2 may directly stimulate B cells came from a WEYAND  ET  AL.  BR1EF  DEFINITIVE  REPORT  1611 
second model.  Treatment  of mice with  600 ug mAb against  L3T4 completely 
inhibited their primary response to antigen (13), however, such L3T4-depleted 
mice produced normal levels of IgM in response to the administration  of rIL-2. 
In  contrast,  ATxBm  mice  failed  to  produce  antibody  in  response  to  rIL-2 
administration  (data not presented). 
Though  we  cannot  exclude  the  possibility  that  rIL-2  acts  on  T  cells  and 
secondarily induces polyclonal IgM secretion, the selective effect of rIL-2 on the 
secretion of IgM antibodies might  reflect the direct activation of a  subset of B 
cells. Ly-1 B cells have been described (14) as a functionally distinct B cell lineage. 
In  autoimmune  mouse strains,  this  B  cell  subpopulation  contains  the  cells re- 
sponsible for spontaneous  IgM  secretion,  as well as those cells producing  IgM 
autoantibodies.  Characteristically,  irradiated  thymectomized  mice  are  missing 
this B cell lineage when reconstituted with bone marrow cells (14). The inability 
of ATxBm mice to respond  to the rIL-2  treatment  support the possibility that 
Ly-1 B cells may play an important role in the observed phenomena.  Additional 
support for this hypothesis comes from the demonstration  that a subpopu]ation 
of the  Ly-1  B  cells contained  in  peritoneal  exudate cells expressed a  molecule 
identified  by  mAb  against  the  IL-2  receptor  (Weyand,  C.,  P.  Lolar,  C.  G. 
Fathman,  and L. Herzenberg,  unpublished observation). 
IL-2 production  and  release  into the  local  microenvironment  seems to be a 
constant feature of every immune response.  We do not know if such local IL-2 
concentrations are comparable to the concentrations achieved by the administra- 
tion  of exogenous  rIL-2  in  this  study.  As  the  administration  of rIL-2  alone 
triggered a humoral immune response against unrelated antigens, immunization 
with a specific antigen  resulting in IL-2 production might be accompanied by a 
polyclonal IgM response.  Indeed, we found elevated IgM titers against KLH in 
mice that had been immunized with SpWMb (Fig. 2). 
The  observed  enhancement  of  the  IgM  response  may  be  of  therapeutic 
relevance. Recent observations in our laboratory suggests that pretreatment with 
rIL-2 can increase the survival of mice subsequently (1 wk later) challenged with 
an  LDs0  dose  of E.  coli.  (Weyand,  C.,  J.  Goronzy,  P.  O'Hanley,  and  C.  G. 
Fathman,  manuscript in preparation). 
Summary 
We studied the potential  immunoenhancing  effects of high doses of rlL-2 on 
murine T  and  B cell functions in vivo. Injection of rIL-2 caused a  threefold or 
more  increase  in  the  frequencies of antigen-specific  proliferative  T  cells,  sug- 
gesting that rIL-2 initiated a polyclonal T cell response. In primary and secondary 
humoral immune responses, administration  of rIL-2 in vivo selectively enhanced 
the  production  of IgM  antibodies,  whereas  the  IgG  response  was  unaffected. 
Coadministration  of rIL-2  with antigen  failed to induce an isotype switch from 
IgM  to  IgG  in  genetically  low-responding  mice.  Interestingly,  in  mice  treated 
with rIL-2 alone (in the absence of exogenous antigen), polyclonal IgM produc- 
tion  was  induced.  Polyclonal  IgM  production  of lesser  magnitude  was  found 
when  mice were immunized  with specific antigen  in the absence of exogenous 
rIL-2,  suggesting that  local  IL-2 concentrations  in a  primary immune response 
might be sufficient to elicit a polyclonal IgM response. 1612  WEYAND ET  AL.  BRIEF  DEFINITIVE REPORT 
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